corrotto Nel nome porta paradigm hf clinical trial amichevole Guaio Ritmico
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis | JACC: Heart Failure
Use of Sacubitril/Valsartan in Heart Failure
Understanding the early mortality benefit observed in the PARADIGM-HF | VHRM
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial - Bhatt - 2021 - European Journal of Heart Failure - Wiley Online Library
Clinical Trial and Biomarker Data | ENTRESTO® (sacubitril/valsartan) | HCP
The PARADIGM-HF trial (reproduced with permission from Wolters Kluwer). 6 | Download Table
Understanding the early mortality benefit observed in the PARADIGM-HF | VHRM
Entresto Use in Heart Failure w Preserved Function – The Early Career Voice
PARADISE MI Trial: Is Sacubitril/valsartan (Entresto) useful in patients with acute MI? – Visualmed
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women - ScienceDirect
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - The Lancet Diabetes & Endocrinology
CardsJC: PARAGON-HF Trial Journal Club - Cardionerds
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF | JACC: Heart Failure
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint | Novartis
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V. - ppt video online download
Emerging Mechanisms in the Management of Heart Failure With Reduced Ejection Fraction
New heart failure agent doubles mortality benefit of ACE inhibitors - PACE-CME
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM
Critical Questions about PARADIGM-HF and the Future
KoreaMed Synapse
PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF - PACE-CME
PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg. - ppt download
Neprilysin: Indications, Expectations, and Challenges | Revista Española de Cardiología